logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

On January 2nd, MILLIONHOPE IND (01897) spent 940 Hong Kong dollars to repurchase 2000 shares.

date
18:08 02/01/2026
avatar
GMT Eight
Mighton Industries (01897) announces that on January 2, 2026, the company repurchased 2000 shares at a cost of 940 Hong Kong dollars, with a repurchase price of 0.47 Hong Kong dollars per share.
MILLIONHOPE IND (01897) announced on January 2, 2026, that the company will spend 940 Hong Kong dollars to buy back 2000 shares, with a repurchase price of 0.47 Hong Kong dollars per share.
Related Articles
HK Stock
BEISEN HOLDING (09669) spent 583,200 Hong Kong dollars on January 2 to repurchase 80,000 shares.
HK Stock
IMPERIUM FIN GP (08029): Lin Junwei appointed as executive director
HK Stock
CSPC PHARMA (01093): Nintedanib Ethanesulfonate Inhalation Powder Aerosol Approved for Clinical Trials in China.
BEISEN HOLDING (09669) spent 583,200 Hong Kong dollars on January 2 to repurchase 80,000 shares.
HK Stock
IMPERIUM FIN GP (08029): Lin Junwei appointed as executive director
HK Stock
CSPC PHARMA (01093): Nintedanib Ethanesulfonate Inhalation Powder Aerosol Approved for Clinical Trials in China.
HK Stock
RECOMMEND
Crossing 2025, Can The Year‑End Rally Extend To The Close? Review Of This Week’s Ten Brokerage Strategies
Crossing 2025, Can The Year‑End Rally Extend To The Close? Review Of This Week’s Ten Brokerage Strategies
icon
29/12/2025
IPO Fundraising Tops The World, A Review Of Ten Key Themes For Hong Kong Stocks In 2025
IPO Fundraising Tops The World, A Review Of Ten Key Themes For Hong Kong Stocks In 2025
icon
29/12/2025
Will The U.S. Market Maintain Its Global Leadership Beyond 2025?
Will The U.S. Market Maintain Its Global Leadership Beyond 2025?
icon
29/12/2025
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.